NLS Pharmaceutics Regains Nasdaq Compliance
Ticker: NCEL · Form: 6-K · Filed: Oct 28, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, listing, nasdaq
Related Tickers: NLS
TL;DR
NLS Pharma back in Nasdaq's good graces, stock should be safe.
AI Summary
On October 28, 2024, NLS Pharmaceutics Ltd. announced it has regained full compliance with Nasdaq listing requirements. This filing incorporates a press release detailing this positive development.
Why It Matters
Regaining compliance with Nasdaq listing rules is crucial for maintaining the company's stock exchange listing and investor confidence.
Risk Assessment
Risk Level: low — The filing reports a positive development of regaining compliance with Nasdaq listing requirements, which is generally a de-risking event.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Nasdaq (company) — Stock Exchange
- October 28, 2024 (date) — Date of Press Release
FAQ
What specific Nasdaq listing requirements did NLS Pharmaceutics Ltd. previously fail to meet?
The filing does not specify which listing requirements were previously unmet, only that full compliance has been regained.
What is the significance of regaining compliance with Nasdaq listing requirements?
Regaining compliance ensures the company's continued listing on the Nasdaq stock exchange, preventing delisting and maintaining investor confidence.
When was the press release announcing this compliance status issued?
The press release was issued on October 28, 2024.
What is the file number for NLS Pharmaceutics Ltd.'s Nasdaq listing?
The filing references Commission file number 001-39957 for NLS Pharmaceutics Ltd.
Are there any financial figures mentioned in relation to regaining compliance?
No specific dollar amounts or financial figures are mentioned in this filing concerning the regaining of Nasdaq compliance.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-10-28 08:00:02
Filing Documents
- ea0218650-6k_nlspharma.htm (6-K) — 11KB
- ea021865001ex99-1_nlspharma.htm (EX-99.1) — 4KB
- 0001213900-24-090964.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 28, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2